The global tissue diagnostics market size is estimated to be worth USD 5.46 billion by 2026 and USD 3.91 billion in 2021, growing at a CAGR of 6.90% during the forecast period.
Tissue-based diagnostic tests are performed to screen, diagnose, and monitor cancer patients' response to therapy. The tissue diagnostics market's scope includes major technologies like In Situ hybridization, IHC, digital pathology and workflow, special staining, and products such as instruments and consumables to determine medical information to diagnose diseases or conditions.
MARKET DRIVERS:
Y-O-Y growth in the incidence or the prevalence of cancer, wide adoption of cancer diagnosis, and developing healthcare infrastructure for cancer diagnosis are majorly escalating the growth rate of the global tissue diagnostics market.
The growing focus of market participants on enhancing advanced tissue-diagnostic-based companion tests is favorable to market growth. In addition, the increasing cancer patients count and high adaption of automated tissue diagnostics to diagnose diseases are expected to enlarge the tissue diagnostics market.
Growing prevalence of cancer, spurring healthcare expenses, and raising funds for research activities for developing cancer treatments are further estimated to contribute to the global tissue diagnostics market growth. For instance, in June 2020, the University of Sheffield United Kingdom collaborated with Zilico Ltd to design and manufacture real-time medical diagnostics to meet particular medical needs. Increasing lifestyle changes, rising food and tobacco consumption, and alcohol and surging common lifestyle disorders are predicted to strengthen the market demand. The increasing number of government initiatives to increase the awareness regarding the efficient early cancer diagnosis to expand the tissue diagnostics the market growth.
The growing aging population across the world is projected to support the global tissue diagnostics market growth.
By 2050, aged people 65 years and above will be two times the fold from 2019, as per the World Population Ageing report 2019. Moreover, 65% of cancer cases and 70% of cancer deaths are seen in older people 65 years and above. The improvement of advanced technologies, high discretionary expenses, and increasing genetic variations bolster the market demand.
Additionally, factors such as increasing investments in research and development of new technologies, the emergence of efficient and accurate products, growing demand for personalized medicines, and untapped market potential due to lack of efficient diagnostics tests for non-small lung cancer detection are expected to provide lucrative opportunities for the growth of tissue diagnostics market. Besides, healthcare centers' rising scale is likely to bolster the demand for the tissue diagnostics market.
MARKET RESTRAINTS:
The factors that restrain the growth of the global tissue diagnostics market are stringent regulations for the approval of new products and instruments that are highly expensive, lack of accessibility to healthcare indicators in underdeveloped countries, and social stigma associated with cancer. In addition, rural areas are less aware of the new technologies in the medical sector, which quietly hamper the market demand.
Impact of COVID-19 on the global tissue diagnostics market:
The World Health Organization (WHO) has declared the pandemic crisis on March 19, 2020. The burden on the healthcare system in several countries is increasing highly. The worldwide economies are witnessing a vastly negative impact of the COVID 19 impact. The healthcare market's research and development showcase a steep fall in sales during the lockdown due to the shutdown of the manufacturing units and scarcity of supply of raw materials, and lack of staffing. Tissue diagnostics purposely used in patients with cancer. Patients with cancer are at high risk of acute coronavirus infection. A significant impact has had on diagnostic labs, particularly testing cell and tissue samples. Tissue diagnostics are widely used to identify the appearance of COVID 19 infection amid the tissues of the patients and exhibit significant traction over the market. The increasing regularity of COVID 19 infection cases with the absence of diagnostic kits to examine surges the demand for testing and screening devices. The examinations have influenced tissue diagnostics virology suppliers to supply recognized testing kits, creating growth opportunities for the tissue diagnostics market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Product Type, Disease, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems. |
This report on the global tissue diagnostics market has been categorized into product type, application, disease, and end-user.
Tissue Diagnostics Market – By Product type:
Based on product type, the consumables segment is ruling the tissue diagnostics market. It has contributed a significant share to the market. It is expected to grow rapidly during the forecast period due to the extensive use of consumables and technology improvements, leading to novel and consumables development.
Tissue Diagnostics Market – By Disease:
Tissue Diagnostics Market – By Application:
Based on the application, the immunohistochemistry segment is likely to contribute a significant share of revenues to the global tissue market over the estimated forecast period. This is due to the rise in the adoption of products developed based on this technology.
Tissue Diagnostics Market – By End-user:
Based on the end-user, the hospital's segment dominates the global tissue diagnostics market and is anticipated to expand further during the forecast period. The significant factors contributing to the growth of this segment are the rise in the number of hospitals, improved accessibility, and availability of test results in hospitals.
Tissue Diagnostics Market – By Region:
Geographically, North America leads the global tissue diagnostics market and is anticipated to grow further during the forecast period. The adoption of the latest technology and the introduction of innovative diagnostics procedures in medical sectors are magnifying the market's growth rate. Owing to the high incidence rate of cancer across regions. The market recorded the largest revenue share in 2020. It is further likely to register robust CAGR during the forecast period. The united states accounted for the significant diagnostics market growth and anticipated contributions to the North American regional market growth. Availability of healthcare infrastructure, accessibility to healthcare facilities, and advancement of technology in the healthcare sectors influence the country's market growth. Simultaneously, the Y-O-Y rise in the prevalence of chronic diseases in the U.S. is further adding boss the growth rate of the regional market. In addition, the United States Precision Medicine Initiative is helping to develop the personalized medicine industry. On the other end, the Canadian market is witnessed to showcase healthy growth during the forecast period.
The European Tissue diagnostics market is growing significantly and more likely to dominate the market with the largest revenue share during the forecast period. The use of human tissue in the production of new experiments is crucial in personalized medicine. Personalized medicine has greatly grown as sequencing technology and healthcare IT programs have become more widely used in clinical workflows, which is expected to drive the Tissue Diagnostics market in the region. Germany, UK, Spain, France, and Italy are the major growth contributors in the region that are expanding the regional market growth. The UK dominates the tissue diagnostics market during the forecast period due to the proliferation of cancer rates. However, government initiatives and favorable reimbursement policies are increasing market growth. Germany and France are more likely to contribute to the European market growth in the coming years.
Asia Pacific market is likely to witness significant growth during the forecast period due to the increasing focus of government and private sectors in developing nations like China, Japan, India, and others. The Asia Pacific is considered one of the fastest-growing regions globally in the tissue diagnostics market. Emerging countries such as China, India, and Japan are significant growing countries in the APAC region. The market growth in the region is attributed to the growing healthcare sector and active key market players. The Indian market is anticipated to witness significant growth in the tissue diagnostics market during the forecast period. The factors, increasing healthcare expenditure, emerging infrastructure for cancer diagnosis, and support by the government are encouraging the market growth in India.
KEY MARKET PARTICIPANTS:
Some of the noteworthy companies dominating the global tissue diagnostic market are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems.
RECENT MARKET DEVELOPMENTS:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product type
5.1.1 Introduction
5.1.2 Instruments
5.1.2.1 Microscope
5.1.2.2 Non-contact Handheld IR Thermometer
5.1.2.3 Haemocytometer
5.1.2.4 NMR Tube
5.1.2.5 Others
5.1.3 Consumables
5.1.3.1 Reagent kits
5.1.3.2 Others
5.1.4 Y-o-Y Growth Analysis, By Product type
5.1.5 Market Attractiveness Analysis, By Product type
5.1.6 Market Share Analysis, By Product type
5.2 Disease
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Lymphoma
5.2.4 Pancreatic cancer
5.2.5 Breast cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Disease
5.2.8 Market Attractiveness Analysis, By Disease
5.2.9 Market Share Analysis, By Disease
5.3 Application
5.3.1 Introduction
5.3.2 Hematoxylin and Eosin
5.3.3 Immunohistochemistry
5.3.4 In Situ Hybridization
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
5.4 End user
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Diagnostic laboratories
5.4.4 Research Organizations
5.4.5 Contract Research Organizations
5.4.6 Biotechnology Companies
5.4.7 Y-o-Y Growth Analysis, By End user
5.4.8 Market Attractiveness Analysis, By End user
5.4.9 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product type
6.1.3.3 By Disease
6.1.3.4 By Application
6.1.3.5 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product type
6.1.4.3 By disease
6.1.4.4 By Application
6.1.4.5 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product type
6.1.5.3 By Disease
6.1.5.4 By Application
6.1.5.5 By End user
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 F. Hoffmann-La Roche AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sigma-Aldrich Co. LLC
8.3 Abbott Laboratories
8.4 Agilent Technologies
8.5 BioGenex
8.6 Danaher Corporation
8.7 Cell Signaling Technology
8.8 Ventana Medical Systems
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
